聯康生物科技集團:年報2023
Liankang Biotechnology Group (00690) announced its 2023 annual results. Revenue reached a record high, with profit reaching HK$70.9 million, a significant increase of 84.04% over the previous year
According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its annual results for the year ended December 31, 2023. The Group's revenue reached a record high, reaching approximately HK$484.7 million, an increase of 10.1% year-on-year. The sales performance of Pina Generic Gin Peptides was exceptional, with year-on-year increases of 15.0% and 9.54%, respectively. Profit during the year reached approximately HK$70.9 million, a significant year-on-year increase of 84.04%, making it an important milestone for a research biopharmaceutical company. General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8% during the year due to the Group's continued internal growth
UNI-BIO GROUP: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Liankang Biotechnology Group (00690.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui March 15 | Liankang Biotechnology Group (00690.HK) issued an announcement. The company's board of directors meeting will be held on March 27, 2024 to review and approve the Group's annual results and announcements for the year ended December 31, 2023, and consider the proposal to pay a final dividend (if any).
UNI-BIO GROUP: DATE OF BOARD MEETING
Uni-Bio Science's Profit to Climb in 2023
Uni-Bio Science Group (HKG:0690) expects to book a profit attributable to the owners of not less than HK$60 million for the financial year 2023, higher than HK$38.5 million a year earlier. The biotech
[Company Yingxi] Liankang Biotechnology Group (00690) expects profit of not less than HK$60 million in 2023
Jinwu Financial News | Liankang Biotechnology Group (00690) issued a positive profit forecast. The Group expects to record profit attributable to parent company owners not less than HK$60 million in 2023 (2022: profit of HK$38.51 million). Based on the information available to the Board of Directors, the Board believes that the expected increase is mainly due to: (1) Sales revenue growth of no less than 10% compared to 2022. Sales revenue for the same period in 2022 was HK$440 million. The increase in related revenue was mainly due to the company's continuous academic promotion, further expanding hospital coverage and suitable patient population, and fully receiving market and
UNI-BIO GROUP: POSITIVE PROFIT ALERT
Liankang Biotechnology Group (00690) cancelled 201 million shares repurchased
Liankang Biotechnology Group (00690) announced that on February 7, 2024, the company cancelled 201 million...
Liankang Biotechnology Group [00690] now reports HK$0.096, an increase of 10.35%
As of 09:31, Liankang Biotechnology Group [00690] reported HK$0.096, up HK$0.009 or 10.35% from yesterday's closing price, with a turnover of HK$0.19 million. Today's high price was HK$0.096 and the lowest price was HK$0.096. Based on yesterday's closing price, the 10-day average price was HK$0.09, and the 50-day average price was HK$0.07. The current price-earnings ratio was 14.26 times, and the 14-day strength and weakness index reported at 48.08.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
On January 24, Liankang Biotechnology Group spent HK$1,6573 million to buy back 17.82 million shares
Liankang Biotechnology Group (00690) issued an announcement to repurchase 17.82 million shares at HK$1,6573 million on January 24, 2024.
Liankang Biotechnology Group (00690) spent HK$1,6573 million to buy back 17.82 million shares on January 24
According to the Zhitong Finance App, Liankang Biotechnology Group (00690) issued an announcement to repurchase 17.82 million shares at HK$1,6573 million on January 24, 2024.
Liankang Biotechnology Group (00690.HK) spent HK$2,056,600 to repurchase 22.38 million shares on January 23
Gelonghui, January 23 | Liankang Biotechnology Group (00690.HK) announced that on January 23, it spent HK$2,056,600 to repurchase 22.38 million shares at a price of HK$0.092-0.091 per share.
Liankang Biotechnology Group (00690.HK): The marketing application for diquafinzol eye drops has been officially accepted by the State Drug Administration
Gelonghui, January 23丨Liankang Biotechnology Group (00690.HK) issued an announcement. The marketing application for diquaphosol eye drops submitted by the Group has been accepted by the China National Drug Administration (“NMPA”). The acceptance number is CYHS2400318. The acceptance marks a key step in the Group's expansion of ophthalmic drug reserves. If successfully approved in the future, it will provide patients with more diverse treatment options.
Changes in Hong Kong stocks | Liankang Biotechnology Group (00690) rose nearly 9%, and the State Drug Administration officially approved the listing of Bogutai
The Zhitong Finance App learned that Liankang Biotechnology Group (00690) rose nearly 9%. As of press release, it had risen 8.7% to HK$0.1, with a turnover of HK$2,067,300. According to the news, Liankang Biotechnology Group announced yesterday that the National Drug Administration (NMPA) approved the marketing application for Bogutai (teriparatide injection) independently developed by the group on January 16, 2024. According to reports, Boghutai (teriparatide injection) is the fifth product launched by the Group after Jinyin Peptide, Jin Yinshu, and Pina popularized Boshutai. It is also the first disposable pre-filled pen-style teriparatide injection made in China.
Uni-Bio Science Group Limited's (HKG:690) Shares Bounce 28% But Its Business Still Trails The Industry
Despite an already strong run, Uni-Bio Science Group Limited (HKG:690) shares have been powering on, with a gain of 28% in the last thirty days. Looking back a bit further, it's encouraging to see
China Grants Uni-Bio Science's Injection for Orthopedic Diseases
China's medical products administrator granted marketing approval for Uni-Bio Science Group's (HKG:0690) Bogutai teriparatide injection for orthopedic conditions, a Monday filing said. The injection i
Liankang Biotechnology Group (00690.HK): Bogutai's marketing application has been officially approved by the State Drug Administration as the first disposable pre-filled teriparatide injection made in China
Gelonghui, January 22丨Liankang Biotechnology Group (00690.HK) announced that China's National Drug Administration (“NMPA”) approved the marketing application for Bogutai (teriparatide injection) independently developed by the Group on January 16, 2024. The application was accepted on June 28, 2022, and the approval number is “Sinopharm Standard S20240004”. Bogutai's approval for listing is a major milestone for the company in the field of orthopedic diseases, expanding the range of drug choices for patients.
Liankang Biotechnology Group (00690.HK) spent HK$264,000 to repurchase 2.98 million shares on January 19
Gelonghui, January 19 | Liankang Biotechnology Group (00690.HK) announced that on January 19, it spent HK$264,000 to repurchase 2.98 million shares at a price of HK$0.09-HK$0.088 per share.
No Data